Clinical Trial Search

Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants

Primary: Number of Participants With Accurate Classification of Irreversible Airflow Obstruction — 10; 5 Participants

Primary: Self-reported Intake of Fruit and Vegetables (Number of Portions Per Day); — 1.9; 6.1 Portions per day

Primary: Spirometry Measurement: Percentage of Predicted Forced Expiratory Volume in 1 Second (FEV1 %Pred) — 75.572; 100.837; 108.311; 111.849 percent of predicted FEV1 — p=<0.0001

Primary: Number of Participants Who Received COPD Prescription for Maintenance Treatment at Baseline — 735; 68; 554; 105 Participants

Primary: Death or Hospitalization, Whichever Occurs First — 34.2; 36.4 Composite events/100 person-years — p=0.52

Primary: ANALYSIS OF LUNG DEPOSITION - Penetration Index — 0.8; 0.72; 0.69; 0.58 ratio

Primary: Change in Flow Mediated Dilation — 0.26; -1.5 percentage of flow mediated dilation

Primary: COPD Diagnosis — 39 participants

Primary: Forced Expiratory Volume in One Second (FEV1), Peak Effect Within 0 - 24 Hours Post-dose — 1.71; 1.79; 1.72; 1.71 L

Primary: Hospital Readmission — 1.12; 1.7 hospital readmissions

Primary: Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - US — 65.6; 64.4 Years

Primary: Pulmonary Microvascular Blood Volume, CV — 0.89; 0.88; 0.92; 0.91 CV — p=0.84

Primary: Rate of Moderate or Severe COPD Exacerbations in Participants With Moderate to Very Severe COPD. — 1.75; 2.11 exacerbations per year — p=0.1042

Primary: Effect of Intervention on Quality of Patient Clinician Communication About End-of-Life Care(QOC) Scale — 23.3; 19.2; 34.0; 25.5 units on a scale — p=0.03

Primary: Percentage of Participants Whose Post-albuterol Forced Expiratory Volume in One Second (FEV1) Was <80% Predicted Normal — 70; 30 percentage of participants

Primary: Pre-dose FEV1 — 1.079; 1.009 Ratio — p=<.0001

Primary: Walking Ability — 369.5; 304.7 meters — p=<0.01

Primary: Number of Subjects With Four Week Continuous Quit Rate (CQR) — 105; 22 participants — p=<0.0001

Primary: Flow-Mediated Dilation (FMD) — 3.1; 6.7; 4.7; 6.9 percentage of change in FMD — p=<0.05

Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) Change From Baseline to 24 Months — -0.004; -0.023; -0.018; -0.035 Liters

Primary: Participation in Tobacco Cessation Treatment — 9; 29 Participants

Primary: Percentage of Participants With COPD Who Rate the Use of the ELLIPTA Inhaler as Easy or Very Easy, Among Those Who Demonstrate Correct Use of the Inhaler at the End of…

Primary: Forced Expiratory Volume in the First Second (FEV1) — 54; 54 Percentage predicted — p=0.09

Primary: Mean Variability in Peak Inspiratory Flow (PIF) — 67.6 Liters/minute

Primary: Dyspnea Intensity — 8.0; 6.5; 7.75; 5 units on a scale

Primary: 6-Minute Walk Test Distance — 25; 37 meters — p=0.189

Primary: Description of Real-life Drug Treatment After Incident Diagnosis - COPD-12 Sample — 35.6; 30.3; 29.1; 25.0 Percentage of Patients

Primary: Safety of Doxycycline, as Measured by the Number of Subjects With Any Treatment-related Adverse Events. — 3; 1 Participants

Primary: Healthcare Utilization — 1080; 920 Participants — p=0.041